Companies /Healthcare

Natera Inc

NASDAQ: NTRA Diagnostics & Research
$328.20
▲ $2.06 (+0.63%) today
Markets open · 3:34pm ET
Today · % change

24/7 Wall St. View

Fundamentals

Market Cap
$47.6B
Profit Margin
-7.1%
Revenue (TTM)
$2.7B
EPS (TTM)
$-1.39
52-Week Range
$157 – $343
Street Target
$338.07

About Natera

Natera Inc is a pioneering diagnostics company that offers a wide range of molecular testing services globally. Its innovative portfolio includes Panorama, a non-invasive prenatal test for chromosomal abnormalities, and Horizon, a carrier screening test. Natera also provides Vistara, Spectrum, Anora, Empower, and a non-invasive prenatal paternity product. Additionally, it offers Signatera for cancer recurrence monitoring, Altera for genomic profiling, Prospera for transplant rejection assessment, and Renasight for kidney gene panel testing. Natera enhances its offerings through partnerships and a cloud-based software, Constellation, facilitating access to its advanced algorithms and bioinformatics. Founded in 2003, Natera is headquartered in Austin, Texas.

NTRA Coverage

11:53am ET
Investing

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

Cathie Wood’s Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary…

Joey Frenette